Home » About Xifaxan550 » Long-term Efficacy

• Long-term Efficacy
• Reduced Hospitalizations
• Long-term Exposure
• Tolerability Profile
• Dosing
• Safety and Side Effects
• FAQs

Long-term* efficacy

Xifaxan 550 mg—breaking the cycle of HE recurrence

*Xifaxan 550 mg is proven to reduce the risk of overt hepatic encephalopathy (HE) recurrence over a 6-month period1

In a randomized, placebo-controlled, double-blind, multicenter, multinational, 6-month study, the efficacy of Xifaxan 550 mg (taken orally 2 times a day) was evaluated in 299 adult subjects. Inclusion criteria: currently in remission (Conn score of 0 or 1) from HE and ≥2 episodes of HE associated with chronic liver disease in the previous 6 months. Lactulose was used concomitantly by 91% of patients (average daily dose of 3.3 cups/day [15 mL/cup]). The primary endpoint was the time to first breakthrough HE episode, defined as a marked deterioration in neurological function (an increase of Conn score to Grade ≥2 or an increase in Conn score and asterixis grade of 1 each if subject entered study at Grade 0).

Xifaxan 550 mg can help patients reduce the risk of overt HE recurrence over a 6-month period

• *In the pivotal clinical trial (N=299), Xifaxan 550 mg reduced the risk of breakthrough HE over a 6-month period by 58% vs placebo (P<0.0001; HR=0.42).
• At 6 months, 78% of patients taking Xifaxan 550 mg (n=140) did not have overt HE recurrence vs 54% with placebo (n=159; 91% concomitant lactulose use in both arms).1

Discover twice-daily dosing.

See how Xifaxan 550 mg may reduce hospitalizations.

IMPORTANT SAFETY INFORMATION

XIFAXAN 550 mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥18 years of age. In the trials of XIFAXAN for HE, 91% of the patients were using lactulose concomitantly. XIFAXAN has not been studied in patients with MELD scores >25, and only 8.6% of patients in the controlled trial had MELD scores over 19. There is increased systemic exposure in patients with more severe hepatic dysfunction. Therefore, caution should be exercised when administering XIFAXAN to patients with severe hepatic impairment (Child-Pugh C).

XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.

Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon which may lead to overgrowth of C. difficile. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.

The most common adverse reactions occurring in >8% of patients in the clinical study were edema peripheral (15%), nausea (14%), dizziness (13%), fatigue (12%), ascites (11%), muscle spasms (9%), pruritus (9%), and abdominal pain (9%).

Complete Prescribing Information.

For product information, adverse event reports, and product complaint reports, please contact:
Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: Salix@medcomsol.com

Reference: 1. Xifaxan [prescribing information]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2010.